Alkem Laboratories has shared an investor presentation detailing the strategic direction for its MedTech division, Alkem MedTech. Key highlights include a focus on the Musculoskeletal and Cardiovascular segments. Crucially, Alkem announced the binding term sheet to acquire a 51%–55% stake in Occlutech Holding AG for an equity value of € 180.70 Million, positioning Alkem to access the global cardiovascular market.
Alkem MedTech Strategic Update
Alkem Laboratories shared an investor presentation outlining the strategic path for its MedTech subsidiary. The presentation confirmed that Alkem MedTech aims to be a significant growth enabler for the entire Alkem Group, focusing on building a comprehensive portfolio across key therapeutic areas.
Priority Segments Identified
Alkem MedTech has prioritized entry into two major segments based on market potential and the company’s right to win:
- Musculoskeletal: Focuses on Knee & Hip implants, utilizing a hybrid approach combining organic technology transfer (with Advita) and manufacturing asset acquisition (with Bombay Ortho). The 5-year vision targets 250 K+ implants sold and a 10% market share in India’s large joints market by Year 5.
- Cardiovascular: This segment focuses on minimally invasive devices, leveraging the planned acquisition of Occlutech. The overall global Cardiovascular Market was valued at $87 Billion in 2025, with India at $0.78 Billion.
Acquisition of Occlutech: A Platform for Cardiovascular Expansion
Alkem MedTech executed a binding term sheet on February 13, 2026, to acquire a controlling stake (51–55%) in Occlutech Holding AG. The total equity valuation for this transaction is € 180.70 Million (Rs. 19,516 Million), funded through internal accruals.
This transaction provides Alkem’s path to success via:
- Established Platform: Occlutech is a leading player in the Structural Heart Occluder market (ranked #2 in Europe and #3 Globally).
- Product Portfolio: Offers a complete portfolio for congenital heart defects, including ASD, PFO, PDA, and AFR devices. Occlutech’s revenue in 2025 was € 50 Million, exhibiting a 14% CAGR (2021-25).
- Synergies: Leveraging Alkem’s brand and reach for expansion.
The completion of the acquisition is expected by June 2026, pending regulatory approvals.
Alkem Laboratories Overview
The presentation noted the strength of the parent entity, Alkem Laboratories Limited, which is the 5th Largest Pharma company in India by %MS. Key parent figures for FY24-25 include:
- Revenue: Rs. 129,645 Million
- Market Capitalization (as of Feb 11, 2026): Rs. 702,444 Million
- Employees globally: >21,000
The Path Ahead
Alkem MedTech plans to drive growth through continuous product innovation, expanding its global presence, enhancing manufacturing capabilities, and establishing a Centre of Excellence for skill development, focusing on both Orthopedics and Cardiovascular businesses.
Source: BSE
